series-a
Stage
2
Investors
About
Cura Therapeutics develops multimodal immunotherapies, including its lead candidate CT101, designed to treat metastatic cancers and age-related diseases by activating immune responses, reducing tumor immunosuppression, and disrupting tumor blood supply.
Explore Cura Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.